Login
Fortress Biotech, Inc. logo

Fortress Biotech, Inc.

fortressbiotech.com

What Do They Do?

Acquires and advances drug candidates through subsidiaries and partners, and commercializes medicines for patients with skin conditions and other diseases.

How Do They Make Money?

Most revenue comes from product deliveries, paid for when customers receive them; Fortress also receives royalties and milestone payments through partner agreements.

revenue
SegmentShareRevenue
Emrosi
Sold outright

24%
Qbrexza
Sold outright

41%
FY2022: 38%
Accutane
Sold outright

21%
FY2022: 26%
Foam franchise products (Amzeeq & Zilxi)
Sold outright

9.6%
Other / legacy product revenue
Sold outright
4.5%

Who Are Their Customers?

The company sells through wholesalers to contracted indirect customers and qualified government healthcare providers; specialty pharmacies also handle its products, and some commercial payers have rebate agreements.

Do Revenues Turn Into Profits?

Yes. It kept 11 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$65.8M.

Operating income, FY2025
−111% of revenue
▲ +36% (Loss) vs FY2024 (−$110.4M, −191%)
Net income, FY2025
11% of revenue
▲ Turned profitable vs FY2024 (−$46M, −80%)
Free cash flow, FY2025
−104% of revenue
▲ +18% (Loss) vs FY2024 (−$80.2M, −139%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +9%
vs $17.6M in Q3 FY2025
Net income
▼ Turned to a loss
vs $5.9M in Q3 FY2025
Qbrexza share of revenue vs 43.2% in Q3 FY2025
  • Nov 13, 2026 Subsidiary licenses a drug candidate for irritable bowel syndrome The licensed drug is in a clinical study for irritable bowel syndrome with diarrhea.

Shrinking. Revenue fell 8% in 4 years, from $68.8M in FY2021 to $63.3M in FY2025, about 2% a year.

New dermatology medicine The newer business section adds Emrosi, an oral rosacea medicine, to Journey's marketed dermatology portfolio; the earlier report's marketed-product list did not include it.

Revenue over time
Emrosi Qbrexza Accutane Foam franchise products (Amzeeq & Zilxi) Other / legacy product revenue Ximino Other Branded Revenue Zilxi Targadox Exelderm Amzeeq Luxamend Collaboration revenue
$100M$50M$0

Who Do They Compete With?

Competes with Galderma Laboratories, Almirall, Leo Pharma, Mayne Pharma, Botanix Pharmaceuticals, and Ortho Dermatologics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support